Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sch-63390 SCHEMBL5823548 | 0.94 | ADORA2A (1.00) | ADORA2AADORA1KDM4ENPC1ALDH1A1 | |
| SCHEMBL7345461 | 0.91 | ADORA2A (1.00) | ADORA2AADORA1KDM4ENPC1ALDH1A1 | |
| SCHEMBL22796280 | 0.91 | ADORA2A (0.85) | ADORA2AADORA1KDM4ENPC1ALDH1A1 | |
| SCHEMBL20694157 | 0.91 | ADORA2A (0.85) | ADORA2AADORA1KDM4ENPC1ALDH1A1 | |
| SCHEMBL7339226 | 0.91 | ADORA2A (1.00) | ADORA2AADORA1KDM4ENPC1ALDH1A1 | |
| SCHEMBL23691785 | 0.91 | ADORA2A (0.85) | ADORA2AADORA1KDM4ENPC1ALDH1A1 | |
| SCHEMBL21588751 | 0.90 | ADORA2A (0.90) | ADORA2AADORA1KDM4ENPC1ALDH1A1 | |
| SCHEMBL14922365 | 0.88 | ADORA2A (0.86) | ADORA2AADORA1KDM4ENPC1ALDH1A1 | |
| SCHEMBL7336459 | 0.88 | ADORA2A (0.81) | ADORA2AADORA1KDM4ENPC1ALDH1A1 | |
| SCHEMBL21588752 | 0.88 | ADORA2A (0.78) | ADORA2AADORA1KDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 972 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | NOVARTIS AG (CH) | 2025-07-03 | — | — | US | claimed |
| US-20250161313-A1 | A METHOD FOR THE TREATMENT OF NEUROPATHY | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-05-22 | — | — | US | claimed |
| US-20250161312-A1 | A METHOD FOR THE TREATMENT OF CHEMOTHERAPEUTIC DRUG-INDUCED NEPHROTOXICITY | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-05-22 | — | — | US | claimed |
| US-12303618-B2 | Oxygen-generating cryogels | NORTHEASTERN UNIVERSITY (US) | 2025-05-20 | — | — | US | claimed |
| CN-119969964-A | Research method for influence on TBI post-impulse behavior | 重庆医科大学 | 2025-05-13 | — | — | CN | claimed |
| EP-4489759-A1 | A METHOD FOR THE TREATMENT OF NEUROPATHY | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2025-01-15 | — | — | EP | claimed |
| EP-4489760-A1 | A METHOD FOR THE TREATMENT OF CHEMOTHERAPEUTIC DRUG-INDUCED NEPHROTOXICITY | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2025-01-15 | — | — | EP | claimed |
| WO-2024216134-A1 | COMBINATORIAL STRATEGIES TO ENHANCE VACCINIA VIRUS IN VITRO AND IN VIVO ONCOLYSIS | UNIVERSITY OF MIAMI (US) | 2024-10-17 | — | — | WO | claimed |
| US-20240219394-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-07-04 | — | — | US | claimed |
| EP-4382612-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-06-12 | — | — | EP | claimed |
| US-20160151374-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | SHERWOOD SERVICES AG (CH) | 2016-06-02 | — | — | US | claimed |
| US-9271985-B2 | Method of using vasoconstrictive agents during energy-based tissue therapy | COVIDIEN AG (CH) | 2016-03-01 | — | — | US | claimed |
| US-20150164903-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | SHERWOOD SERVICES AG (CH) | 2015-06-18 | — | — | US | claimed |
| US-20140271606-A1 | METHODS OF USING ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING BLEEDING DISORDERS | BAYER HEALTHCARE LLC | 2014-09-18 | — | — | US | claimed |
| US-7767686-B2 | Method of using adenosine receptor blockers during tissue ablation | COVIDIEN AG (CH) | 2010-08-03 | — | — | US | claimed |
| US-20080275068-A1 | administering a vasoconstrictive agent such as an adenosine receptor antagonist ( 1,3-dipropyl-8-cyclopentylxanthine, 8-(3-Chlorostyryl)caffeine, 6-carboxy-methyl-5,9-dihydro-9-methyl-2-phenyl-[1,2,4]-triazolo[5,1-a][2,7]naphthyridine) to the mammal to increases the size of the coagulation zone | COVIDIEN AG (CH) | 2008-11-06 | — | — | US | claimed |
| US-20070208042-A1 | Method of using vasoconstrictive agents during energy-based tissue therapy | SHERWOOD SERVICES AG | 2007-09-06 | — | — | US | claimed |
| US-20070207979-A1 | Method of using adenosine receptor blockers during tissue ablation | SHERWOOD SERVICES AG | 2007-09-06 | — | — | US | claimed |
| EP-1300147-A1 | Purine compounds and adenosine A2 receptor antagonist as preventive or therapeutic agent for diabetes mellitus | Eisai Co. Ltd (JP) | 2003-04-09 | — | — | EP | claimed |
| EP-1054012-A1 | PURINE DERIVATIVES AND ADENOSINE A2 RECEPTOR ANTAGONISTS SERVING AS PREVENTIVES/REMEDIES FOR DIABETES | Eisai Co., Ltd. (JP) | 2000-11-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161313-A1 | A METHOD FOR THE TREATMENT OF NEUROPATHY | ADORA2A, P2RX2, ADORA2B | ADORA2A 1/4885ADORA1 12/4885KDM4E 1434/4885 |
| US-20070207979-A1 | Method of using adenosine receptor blockers during tissue ablation | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA1 4/4885KDM4E 4216/4885 |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | HAVCR2, LGALS3BP, CD274 | ADORA2A 1416/4885ADORA1 2549/4885KDM4E 3970/4885 |
| US-20070208042-A1 | Method of using vasoconstrictive agents during energy-based tissue therapy | PLAT, TEK, PLG | ADORA2A 271/4885ADORA1 503/4885KDM4E 3340/4885 |
| US-20250161312-A1 | A METHOD FOR THE TREATMENT OF CHEMOTHERAPEUTIC DRUG-INDUCED NEPHROTOXICITY | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA1 5/4885KDM4E 1738/4885 |
| US-20150164903-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | PLAT, TEK, PLG | ADORA2A 271/4885ADORA1 503/4885KDM4E 3340/4885 |
| US-20160151374-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | PLAT, TEK, PLG | ADORA2A 271/4885ADORA1 503/4885KDM4E 3340/4885 |
| US-20080275068-A1 | administering a vasoconstrictive agent such as an adenosine receptor antagonist ( 1,3-dipropyl-8-cyclopentylxanthine, 8-(3-Chlorostyryl)caffeine, 6-carboxy-methyl-5,9-dihydro-9-methyl-2-phenyl-[1,2,4]-triazolo[5,1-a][2,7]naphthyridine) to the mammal to increases the size of the coagulation zone | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885KDM4E 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.